Related people (22)
Johan Auwerx
Johan Auwerx is Professor at the École Polytechnique Fédérale in Lausanne, Switzerland, where he occupies the Nestle Chair in Energy Metabolism. Dr. Auwerx has been using molecular physiology and systems genetics to understand metabolism in health, aging and disease. Much of his work focused on understanding how diet, exercise and hormones control metabolism through changing the expression of genes by altering the activity of transcription factors and their associated cofactors. His work was instrumental for the development of agonists of nuclear receptors - a particular class of transcription factors - into drugs, which now are used to treat high blood lipid levels, fatty liver, and type 2 diabetes. Dr. Auwerx was amongst the first to recognize that transcriptional cofactors, which fine-tune the activity of transcription factors, act as energy sensors/effectors that influence metabolic homeostasis. His research validated these cofactors as novel targets to treat metabolic diseases, and spurred the clinical use of natural compounds, such as resveratrol, as modulators of these cofactor pathways. Johan Auwerx was elected as a member of EMBO in 2003 and is the recipient of a dozen of international scientific prizes, including the Danone International Nutrition Award, the Oskar Minkowski Prize, and the Morgagni Gold Medal. His work is highly cited by his peers with a h-factor of over 100. He is an editorial board member of several journals, including Cell Metabolism, Molecular Systems Biology, The EMBO Journal, Journal of Cell Biology, Cell, and Science. Dr. Auwerx co-founded a handful of biotech companies, including Carex, PhytoDia, and most recently Mitobridge, and has served on several scientific advisory boards. Dr. Auwerx received both his MD and PhD in Molecular Endocrinology at the Katholieke Universiteit in Leuven, Belgium. He was a post-doctoral research fellow in the Departments of Medicine and Genetics of the University of Washington in Seattle.
Michel Aguet
Dr. Michel Aguet, MD, held positions in academia and industry (Associate Professor at the Institute of Molecular Biology, University of Zürich; Head of Molecular Oncology, Genentech, So. San Francisco) before he was appointed director of the Swiss Institute for Experimental Cancer Research (ISREC) (1996-2009). In the context of the integration of ISREC into the Swiss Federal Institute of Technology (EPFL), he was appointed as Full Professor at the newly established School of Life Sciences in 2005. From 2001-2013 he directed the National Center of Competence in Research (NCCR) in Molecular Oncology, a national program launched by the Swiss National Science Foundation to encourage translational cancer research and for which ISREC was the leading house. Dr. Aguet has been a SAB member in the pharmaceutical industry, biotech industry and venture capital industry since 1997. A large part of his scientific career was devoted to exploring the molecular biology of interferons (cloning of the interferon gamma receptor, generation of various interferon signaling mutants in the mouse) and, in collaboration with Prof. Charles Weissmann, to investigating the role of prion related protein PrP in mouse prion disease models. In recent years his research focused on characterizing the role of BCL9 proteins, which are part of the Wnt/beta-catenin transcriptional activation complex, in regulating stem cell traits in intestinal epithelium and colorectal cancer. His laboratory is now closed due to retirement.
Horst Vogel
Horst Vogel est né en 1948 à Würzburg, Allemagne. Après ses études en chimie, il obtient le diplôme de chimie en 1974 de l'Université de Würzburg.Il entreprend ensuite un travail de doctorat au Max-Planck Institut für Biophysikalische Chemie de Göttingen, et obtient en 1978 le grade de docteur ès sciences de l'Université de Göttingen. De 1978 à 1983 il effectue des recherches au Max-Planck Institut für Biologie à Tübingen et en 1984, il rejoint le Biocentre à Bâle où il travaille jusqu'en 1989, effectuant une année au Karolinska Institute à Stockholm. En 1989, Horst Vogel rejoint l'institut de chimie physique de l'EPFL où il dirige un groupe travaillant dans les domaines de la biophysique et de la bioélectronique. Depuis le 1er octobre 1994 il est profeseur en chimie physique des polymères et membranes au Département de chimie de EPFL. Ses intérêts de recherche sont l'étude de la structure et de la dynamique de récepteurs membranaires et l'auto-assemblage des biomolécules aux interfaces pour développer de nouveaux biocapteurs dans le domaine de micro- et nanotechnologie. Il enseigne les sciences du vivant, la biophysique et biochimie, et des chapitres concernant la biotechnologie. Dipl. in Chemistry1974-Univ. Würzburg, DE Ph.D.-1978-MPI für Biophys. Chemie, Göttingen, DE
Urs von Stockar
Originaire de Zurich, Urs von Stockar est né en1942. Ingénieur chimiste diplômé de l'EPFZ en 1967, il y est ensuite assistant au Laboratoire de chimie technique et, en 1973, soutient sa thèse couronnée par la médaille d'argent de l'EPFZ. De 1973 à 1976, il travaille au département de génie chimique de l'Université de Californie. Il y enseigne et participe au développement d'un procédé technique pour la conversion biologique de la cellulose en alcool. En 1977, il est ingénieur chimiste chez Ciba-Geigy. Fin 1977 il est nommé professeur extraordinaire à l'EPFL. Il dirige l'Institut de génie chimique en 1978/79 et en 1989/90. Il est professeur ordinaire en 1982. En 1982/83 et 1993/95, il dirige le Département de chimie. Son enseignement et sa recherche traitent des opérations de transfert de masse et de la biotechnologie, il s'intéresse également aux questions de bioénergétique et de biothermodynamique. Collaborant avec l'UNIL et l'ISREC, son équipe développe des procédés de fabrication d'anticorps monoclônaux spéciaux, capables de protéger les muqueuses humaines. En 1990 il est nommé professeur associé à l'Université de Genève. Il représente la Suisse dans un groupe d'experts de la Fédération européenne de biotechnologie. Après avoir siégé pendant plusieurs années dans son Comité de direction, il a été nommé président de la Fédération Européenne de Biotechnologie pour la période 1996-97. Depuis 1991, il dirige le Comité de coordination suisse pour la biotechnologie. Diploma in Chemical Eng.-1967-ETHZ, CH Ph.D.-1972-ETHZ, CH Postdoc. Fellow-1973-76-Univ. of California, Berkeley, US
César Pulgarin
Prof. C. Pulgarin is Chemist from Lausanne University, Master in environmental chemistry from Geneva University, Ph D in synthesis bio-inspired of natural substances from Neuchâtel University. During his education he carried out several industrial trainings. Since March 1989, he has been working at the EPFL where he is leader of the Advanced Oxidation Processes Group (GPAO) active in the development chemical, photochemical, electrochemical, ultrasonic processes, their coupling between them and with biological systems to degrade chemical and microbiological pollutants in water and air. He has an H index of 40 and he is the world most cited author in 1) TiO2 photo-assisted bacterial inactivation in water and 2) Coupling of photochemical and biological processes for pollutant degradation. He has been involved in ten African, South American and European international research projects. He has been Swiss representative in COST program 540.
Florian Maria Wurm
Florian Wurm received his academic training as a Biologist and Molecular Geneticist at the University of Giessen. He joined the Hoechst AG (Behringwerke) in Marburg as head of a laboratory in Virology. Working with immortalized mammalian cells for the establishment of production processes for alpha-interferons provided the first opportunity to combine basic research with medical application. In 1984 he joined Harvard Medical School in Boston as a Research Fellow in Molecular Biology. 1986 he took an offer from Genentech Inc. in San Francisco to work in Process Sciences on the development of large scale manufacturing processes for recombinant proteins. There he has held a number of leading positions and has acquired intimate knowledge in the generation of protein pharmaceuticals in mammalian cells in bioreactors (a number of which are now marketed products).  In 1995 he joined the EPFL as a Professor for Biotechnology. Wurm has published more than 250 scientific papers and holds more than 20 patents/patent-applications. His H-index stands at 60 in 2021.  He was Chairman (2005-2009) and is member of the Executive Board of the European Society of Animal Cell Technology (ESACT). He serves as a consultant to the pharmaceutical Biotech Industry, mainly in the fields of animal cell technology for recombinant protein production and in regulatory affairs. He works as a scientific reviewer and editior/asscciate editor for a number of international journals in the Biotech field. F.M. Wurm teaches classes to pre- and postgraduate students in the fields of Molecular and Cellular Biotechnology. He was founder and Chief Scientific Officer of ExcellGene SA, a 2001 established company in Monthey, Switzerland. He took the position of President and CEO of ExcellGene in 2015. He retired from the CEO position in 2017 and continues to be President and Chief Scientific Officer of ExcellGene. In 2008 Dr. Wurm was appointed Visiting Professor for Biotechnology at Jinan University in Guangzhou, China.   He retired from his position at the EPFL in 2015. His laboratory is closed. With his team at ExcellGene and in collaboration with Dr. Paco Pino, Director of R&D, he continues to explore manufacturing sciences with animal cells in bioreactors.

Graph Chatbot

Chat with Graph Search

Ask any question about EPFL courses, lectures, exercises, research, news, etc. or try the example questions below.

DISCLAIMER: The Graph Chatbot is not programmed to provide explicit or categorical answers to your questions. Rather, it transforms your questions into API requests that are distributed across the various IT services officially administered by EPFL. Its purpose is solely to collect and recommend relevant references to content that you can explore to help you answer your questions.